

ILCA 2016

International Liver Cancer Association

10th Annual Conference

9 ▶ 11 September 2016

Vancouver, Canada

Fairmont Hotel Vancouver



ILCA

International Liver Cancer Association



ABSTRACT SUBMISSION

16 April 2016

EARLY REGISTRATION

8 July 2016

LATE REGISTRATION

12 August 2016

ONSITE FEE

As of 13 August 2016

**The international
multidisciplinary
forum for liver
cancer experts
around the latest
innovations in
research and care**

CONFERENCE HIGHLIGHTS:

- State-of-the-Art Lectures
- Cutting Edge Symposia
- General Sessions
- Interactive Luncheon Workshops
- e-Poster Viewing Tours
- Industry Exhibition
- Networking Breaks and Reception

Register now online

www.ilca2016.org

The Conference



ILCA 2016

9 ▶ 11 September VANCOUVER, CANADA

Priming Knowledge in Liver Cancer across Disciplines

ILCA is looking forward to its second trip to Canada – this time in the breath-taking city of Vancouver. This year's meeting will be very special as it marks the 10th Anniversary of ILCA. Indeed it has been 10 years since our association started advancing research in the pathogenesis, prevention, and treatment of liver cancer. ILCA successfully continues to organise Annual Conferences to all parts of the world offering a programme with a multidisciplinary and transversal approach and with the objective to encourage and stimulate scientific debate and networking between liver cancer experts from all regions.

This multidisciplinary meeting is an outstanding scientific forum for all clinical, translational and basic researchers, physicians and allied professionals across liver cancer related disciplines to exchange their experiences and best practices. Distinguished international speakers will enrich the scientific programme through state-of-the-art lectures, symposia, workshops and abstract presentations.

Contributions from Participants

All participants are invited to make submissions for adjudication by an Abstract Review Committee. The Committee will accept or reject the work according to the relevance to ILCA, objectivity of statements, suitability of methods, conclusions confirmed by objective results, scientific value, originality of work and overall impression. Selected submissions considered to have especially broad appeal will be assigned to General Sessions for presentation as Oral Communications. All other accepted submissions will be presented in e-Poster format. Both of the e-Poster viewing tours will be opened by one of the ILCA prominent scientists and be partly dedicated to 15 top scored abstracts within each session, presented in paper board poster format.

How to Submit an Abstract

Abstracts may only be submitted electronically through the conference website www.ilca2016.org. The abstract submissions open on 18 January 2016. Abstracts should address all aspects of liver cancer with a clear emphasis on maximizing focus, exchange and results. **The deadline for abstract submissions is 16 April 2016.** Please visit www.ilca2016.org to review abstract categories and submission guidelines.

Speakers Information



Napoleone Ferrara, MD (USA)

Napoleone Ferrara earned his MD degree in 1981 from the University of Catania Medical School in Italy. After completing his postdoctoral research at the University of California, San Francisco, Dr. Ferrara joined Genentech Inc. in 1988. It is there where he spent nearly 25 years working on the isolation, molecular cloning and biological characterisation of VEGF-A which resulted in the development of bevacizumab, the first anti-angiogenic agent to be approved by the FDA for cancer therapy. His research also led to the development of ranibizumab, which has been FDA-approved for the treatment of multiple intraocular neovascular disorders. In December 2012, Dr. Ferrara joined the University of California, San Diego as a Distinguished Professor of Pathology, Distinguished Adjunct Professor of Ophthalmology, and Senior Deputy Director for Basic Science of the Moores Cancer Center.



Paul Monga, MD (USA)

Dr. Satdarshan (Paul) Singh Monga is a Professor of Pathology and Medicine at the University of Pittsburgh, School of Medicine. He is also the Endowed Chair for Experimental Pathology, Vice Chair and Chief of the Division of Experimental Pathology and Assistant Dean for the Medical Scientists Training Program. His research is focused on elucidating the cellular and molecular basis of liver pathophysiology including that of hepatic tumours such as hepatoblastoma and hepatocellular cancer. Using patient tissues, animal models and cell lines, his group has identified an important role of aberrant β -catenin signaling as well as its cooperation with other signaling pathways such as Hippo, HGF/Met and others in various hepatic tumours. His research is funded by the National Institutes of Health, private pharmaceutical companies, and foundations such as St. Baldrick's.



Irene O.L. Ng, MD, PhD (Hong Kong)

Irene Ng Oi-lin is Chair Professor and Head of Department of Pathology at The University of Hong Kong and Loke Yew Professor in Pathology. She is also the Director of the State Key Laboratory for Liver Research. Prof. Ng's research work focuses on the molecular pathogenesis of liver cancer, including liver cancer stem cells and identification and characterisation of important genes and signaling pathways. She has established useful pathological and biological parameters with prognostic significance for patient management. Her research studies have provided insight in the understanding of liver cancer development and may help identify potential targets in novel cancer therapy. She has published more than 300 peer-reviewed journal articles. She is among the top 1% of most cited scientists in 'Clinical Medicine' and 'All Fields' of ISI Essential Science Indicators.



Bruno Sangro, MD, PhD (Spain)

Bruno Sangro is Director of the Liver Unit at Clinica Universidad de Navarra, Aggregate Professor of Medicine at the University of Navarra School of Medicine, Head of the Area of Digestive and Metabolic Diseases at the Navarra Institute for Research and Head of the group for Translational Research in Hepatology in the National Biomedical Research Network Center for Liver and Digestive Diseases. He is also advisor for the Spanish and the European Agency for Medicinal Products. His basic and clinical research has mainly focused on liver cancer, with a high priority on therapeutic innovation. The Liver Unit of Clinica Universidad de Navarra has pioneered several approaches to the treatment of liver cancer from expanded criteria for liver transplantation to locoregional vascular therapy including intraarterial infusion chemotherapy, transarterial embolization and radioembolization, and systemic advanced therapies including gene therapy or immunotherapy.

- General Session
- Industry Symposium
- Symposium
- Workshop
- State-of-the-Art Lecture

The Programme

Thursday, 8 September 2016

- 13:00 – 19:00** Pre-Conference Workshop on Pre-Clinical Models of HCC: From Target Identification to Clinical Trials
The pre-conference workshop is subject to an additional registration. To attend this workshop, full conference registration is compulsory.

Friday, 9 September 2016

- 08:00 – 09:30** **ILCA Symposium 1: New Targets in Hepatocellular Carcinoma**
 Chairs: Richard Finn, MD (USA) and Peter R. Galle, MD, PhD (Germany)
 - **SIRT6 – An Epigenetic Player in Liver Differentiation and Cancer**
Susanne Strand, PhD (Germany)
 - **Beta-catenin Mutations in HCC: Biological and Therapeutic Implications**
Paul Monga, MD (USA)
 - **Hepatocellular Carcinoma – Liver Cancer Stem Cells**
Irene Ng, MD, PhD (Hong Kong)
 - **Therapeutic Targeting of IGF2 in Liver Cancer**
Daniela Sia, PhD (Italy)
- 09:30 – 10:30** **State-of-the-Art Lecture 1**
 Chair: Andrew X. Zhu, MD (USA)
- 10:30 – 11:00** Coffee and Networking Break
- 11:00 – 11:15** **Welcome Address**
 Richard Finn, MD (USA), Jessica Zucman-Rossi, MD, PhD (France), Morris Sherman, MD, PhD (Canada) and Peter R. Galle, MD, PhD (Germany)
- 11:15 – 12:45** **General Session 1**
- 12:45 – 13:00** Session Break
- 13:00 – 14:30** **Diamond Partner Lunch Symposium**
- 14:30 – 14:45** Session Break
- 14:45 – 16:15** **General Session 2**
- 16:15 – 16:45** Coffee and Networking Break
- 16:45 – 18:15** **ILCA Symposium 2: Controversies in Liver Cancer (Pros and Cons Session)**
 Chairs: Masatoshi Kudo, MD, PhD (Japan) and Kwang-Hyub Han, MD (Republic of Korea)
 - **Y90 vs. TACE**
Bruno Sangro, MD, PhD (Spain) vs. Valérie Vilgrain, PhD (France)
 - **What to Expect After Sorafenib?**
Ann-Lii Cheng, MD, PhD (Taiwan) vs. Jordi Bruix, MD (Spain)
 - **Transplant Beyond Milan**
Gonzalo Sapisochin, MD (Canada) vs. Francis Yao, MD (USA)
 - **Assessment of Tumour Response After Treatment**
David Lu, MD (USA) vs. Haesun Choi, MD (USA)
- 18:15 – 19:00** **Welcome Reception**

Saturday, 10 September 2016

- 07:30 – 08:30** **Industry Partner Symposium**
- 08:30 – 10:00** **General Session 3**
- 10:00 – 11:00** e-Poster Viewing Tour and Networking Break
- 11:00 – 12:30** **Plenary Session**
- 12:30 – 12:45** Session Break
- 12:45 – 14:00** **ILCA Special Interest Groups (SIGs) Luncheon Workshops**
- **SIG Molecular Classification and Signalling Pathways Single Cell Genome in Liver Cancer**
Xin Wei Wang, PhD (USA) and Keji Zhao, PhD (USA)
 - **SIG Surveillance, Biomarkers and Molecular Pathology Biomarkers: A Review of the Present and a Glimpse of the Future**
Amit Singal, MD (USA)
 - **SIG Liver Surgery and Transplantation Liver Transplantation vs. Resection for Hepatocellular Carcinoma**
Katsuhiko Yanaga, MD, PhD (Japan)
 - **SIG Imaging and Loco-Regional Therapies**
Riad Salem, MD (USA)
 - **SIG Target and Systemic Therapies Emerging Systemic Therapies on Advanced Hepatocellular Carcinoma**
Joong-Won Park, MD, PhD (Republic of Korea) and Tim Meyer, MD, PhD (United Kingdom)
 - **SIG Non-HCC Hepatic Malignancies An Update on Risk Factors for Cholangiocarcinoma**
Shahid A. Khan, MD, PhD (United Kingdom)

- 14:00 – 14:15** Session Break
- 14:15 – 15:45** **General Session 4**
- 15:45 – 16:45** e-Poster Viewing Tour and Networking Break
- 16:45 – 18:15** **ILCA Symposium 3: What is New in Adenoma?**
 Chairs: Peter Schirmacher, MD, PhD (Germany) and Massimo G. Colombo, MD (Italy)
 - **Molecular Classification of Hepatocellular Adenomas in Clinical Practice**
Jean-Charles Nault, MD (France)
 - **What is New in Hepatocellular Adenoma Morphological Types?**
Valérie Paradis, MD, PhD (France)

Sunday, 11 September 2016

- 07:30 – 08:30** **Industry Partner Symposium**
- 08:30 – 09:15** **ILCA General Assembly**
- 09:15 – 09:45** Coffee and Networking Break
- 09:45 – 10:45** **State-of-the-Art Lecture 2: Angiogenesis: From Bench to Clinic**
 Speaker: Napoleone Ferrara, MD (USA)
- 10:45 – 12:15** **General Session 5**
- 12:15 – 12:30** **Closing Ceremony**

Registration

Registration must be completed online at www.ilca2016.org

Conference Registration Fees

	Early registration 8 July 2016	Late registration 12 August 2016	Onsite fee As of 13 August 2016
ILCA Member*	€ 325	€ 425	€ 475
ILCA Non-Member	€ 550	€ 600	€ 650
Student, Scientist in training**	€ 150	€ 175	€ 200
Accompanying person***	€ 150	€ 160	€ 170

* Please note that ILCA delegates who have not paid their membership dues by 26 August 2016 will not be granted the reduced registration fee. To apply for or renew your membership, please visit www.ilca-online.org

** This fee is only available to those students who do not yet have their degree. A copy of your student ID card must be provided upon registration

*** The accompanying person's registration fee includes entrance to the Welcome Reception and all scheduled coffee breaks and lunches.

Cancellation and Refund Policy:

Until 12 August 2016: a € 50 cancellation fee will be applied to process the refund of registration fees.

As of 13 August 2016: no refund of registration fees will be possible.

All refunds are subject to prevailing exchange rates. Refunds will be made following the conference in the same manner as the original payment was received. If bank charges apply, they will be deducted from the refunded amount.

Venue

The venue for ILCA 2016 is the **Fairmont Hotel Vancouver**.

Fairmont Hotel Vancouver is known as the "Castle in the City" and reflects timeless luxury and history of the city. Holding a prime downtown location, steps from Vancouver shopping, dining and entertainment, it is the perfect place to enjoy Vancouver's vibrant atmosphere.

Reserved rooms at the Fairmont Hotel Vancouver – with specially reduced rates for ILCA 2016 participants – are available.

Please visit the www.ilca2016.org website for further information.

Join and Participate in ILCA

Membership in ILCA provides you with exclusive benefits such as reduced registration rates to our Annual Conferences and to the ILCA Schools of Liver Cancer, access to exclusive resources, active involvement in two of the six ILCA Special Interest Groups and the opportunity to engage with ILCA around the ILCA Fellowship Programme and the ILCA School.

Your membership is also essential to support ILCA's initiatives and to help progress its mission to advance research in the pathogenesis, prevention, and treatment of liver cancer. We invite you to discover more about ILCA's initiatives and to connect with our expanding group of HCC experts from various fields and from around the world. To join ILCA and participate in its initiatives, please visit www.ilca-online.org

Pre-Conference Workshop on Pre-Clinical Models of HCC: From Target Identification to Clinical Trials

Thursday, 8 September 2016

Registration fees	
ILCA Member*	€ 125
ILCA Non-Member	€ 150

To attend this workshop, full conference registration is compulsory.

Objectives:

- Understanding the need for precision liver cancer models due to liver tumour molecular heterogeneity and complex tumour microenvironment
- Grasping current models and their pros and cons
- Developing consensus criteria to define most clinically relevant pre-clinical models
- Discussing challenges and recommending solutions

Hotel rates at Fairmont Hotel Vancouver

Occupancy	Rates
Fairmont Room	219 CAD*
Fairmont Gallery	239 CAD*
Fairmont Deluxe	249 CAD*
Junior Suite	269 CAD*

* Room rate does not include breakfast, applicable VAT nor hotel specific fees in effect at the time of the meeting.

ILCA Governing Board

Executive Committee

President

Richard Finn (USA)

Executive Secretary

Jessica Zucman-Rossi (France)

Treasurer

Morris Sherman (Canada)

Past President

Peter R. Galle (Germany)

Council

Ann-Lii Cheng (Taiwan)

Sandrine Faivre (France)

Norihiro Kokudo (Japan)

Riad Salem (USA)

Bruno Sangro (Spain)

Peter Schirmacher (Germany)

Myron Schwartz (USA)

Xin Wei Wang* (USA)

* Liaison in an advisory capacity without fiduciary duties

Contact us

International Liver Cancer Association (ILCA)

Boulevard du Souverain, 280

B-1160 Brussels – Belgium

Tel: +32 2 789 2345

Fax: +32 2 743 1550

Email: info@ilca-online.org

Website: www.ilca-online.org

www.ilca2016.org • www.ilca-online.org

